Repurposing Chlorpromazine in the Treatment of Glioblastoma
Status:
Recruiting
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
This study evaluates the addition of chlorpromazine to the first-line therapeutic protocol,
i.e. maximal well-tolerated surgical resection followed by radiotherapy plus concomitant and
adjuvant chemotherapy with temozolomide, in newly diagnosed glioblastoma multiforme patients
carrying a hypo-methylated O6-methylguanine-DNA-methyltransferase (MGMT) gene
Phase:
Phase 2
Details
Lead Sponsor:
Marco G Paggi, MD, PhD
Collaborators:
Carlo Besta Neurological Institute Istituto Oncologico Veneto IRCCS Regina Elena Cancer Institute